Vulvar, vaginal pre-cancer rates decreased after HPV vaccine was introduced

January 7, 2022

January 6, 2022

High-grade vulvar, vaginal and anal precancer rates decreased or stabilized after the introduction of the HPV vaccine, according to findings published in the American Journal of Preventive Medicine.

“HPV causes nearly all cervical cancers and a large proportion of vaginal, vulvar, and anal cancers,” Mona Saraiya, MD, MPH, a medical officer and team lead of the CDC’s Division of Cancer Prevention and Control’s Epidemiology and Applied Research Branch, and colleagues wrote.

Vaccine-type HPV infections, anogenital warts, cervical precancers and invasive cervical cancers have decreased in the U.S. since the introduction of the HPV vaccine to girls in 2006 and boys in 2011, they added.

Saraiya and colleagues examined the incidence rates of intraepithelial lesions grade 3 vulvar, vaginal and anal precancers among individuals aged 15 to 39 years. Using 2000 to 2017 data from select cancer registries, the data covered 27.8% of the U.S. population that required reporting of these precancers.

Read more at Healio.

Immunize Colorado